|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
|
US6923964B1
(en)
|
1997-12-02 |
2005-08-02 |
Neuralab Limited |
Active immunization of AScr for prion disorders
|
|
US6905686B1
(en)
|
1997-12-02 |
2005-06-14 |
Neuralab Limited |
Active immunization for treatment of alzheimer's disease
|
|
US6787523B1
(en)
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
|
TWI239847B
(en)
*
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
|
US6913745B1
(en)
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
US6750324B1
(en)
|
1997-12-02 |
2004-06-15 |
Neuralab Limited |
Humanized and chimeric N-terminal amyloid beta-antibodies
|
|
US6761888B1
(en)
*
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
|
US7179892B2
(en)
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7964192B1
(en)
*
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US20050059802A1
(en)
*
|
1998-04-07 |
2005-03-17 |
Neuralab Ltd |
Prevention and treatment of amyloidogenic disease
|
|
US20030147882A1
(en)
|
1998-05-21 |
2003-08-07 |
Alan Solomon |
Methods for amyloid removal using anti-amyloid antibodies
|
|
US6787637B1
(en)
|
1999-05-28 |
2004-09-07 |
Neuralab Limited |
N-Terminal amyloid-β antibodies
|
|
UA81216C2
(en)
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
|
DK1409654T3
(da)
|
1999-06-16 |
2008-12-08 |
Boston Biomedical Res Inst |
Immunologisk styring af beta-amyloid-niveauer in vivo
|
|
WO2001062801A2
(en)
|
2000-02-24 |
2001-08-30 |
Washington University |
Humanized antibodies that sequester amyloid beta peptide
|
|
PE20020574A1
(es)
|
2000-12-06 |
2002-07-02 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido amiloideo beta
|
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
|
EP2165714B1
(en)
*
|
2001-04-30 |
2013-10-23 |
Eli Lilly And Company |
Humanized antibodies recognizing the beta-amyloid peptide
|
|
EP1385544B1
(en)
*
|
2001-04-30 |
2008-09-24 |
Eli Lilly And Company |
Humanized antibodies
|
|
WO2003000714A2
(en)
*
|
2001-06-22 |
2003-01-03 |
Panacea Pharmaceuticals, Inc. |
Compositions and methods for preventing protein aggregation in neurodegenerative diseases
|
|
WO2003014162A1
(en)
†
|
2001-08-03 |
2003-02-20 |
Medical & Biological Laboratories Co., Ltd. |
ANTIBODY RECOGNIZING GM1 GANGLIOSIDE-BOUND AMYLOID β-PROTEIN AND DNA ENCODING THE ANTIBODY
|
|
US20060073149A1
(en)
*
|
2001-08-17 |
2006-04-06 |
Bales Kelly R |
Rapid improvement of cognition in condition related to abeta
|
|
US20040241164A1
(en)
*
|
2001-08-17 |
2004-12-02 |
Bales Kelly Renee |
Use of antibodies having high affinity for soluble ab to treat conditions and diseases related to ass
|
|
ES2391905T3
(es)
*
|
2001-08-17 |
2012-11-30 |
Washington University |
Método de ensayo para la enfermedad de alzheimer
|
|
WO2003016466A2
(en)
*
|
2001-08-17 |
2003-02-27 |
Eli Lilly And Company |
ANTI-Aβ ANTIBODIES
|
|
DE60224200T2
(de)
*
|
2001-08-17 |
2008-07-10 |
Eli Lilly And Co., Indianapolis |
Assayverfahren für alzheimer-krankheit
|
|
US7179606B2
(en)
*
|
2001-11-23 |
2007-02-20 |
Syn X Pharma, Inc. |
IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's disease
|
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
ATE419871T1
(de)
*
|
2002-04-25 |
2009-01-15 |
Lilly Co Eli |
Verfahren zur behandlung von angststörungen bei älteren personen
|
|
WO2004029629A1
(en)
*
|
2002-09-27 |
2004-04-08 |
Janssen Pharmaceutica N.V. |
N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
|
|
FR2846667B1
(fr)
*
|
2002-11-06 |
2004-12-31 |
Pasteur Institut |
Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
|
|
AU2003303198A1
(en)
|
2002-12-19 |
2004-07-14 |
New York University |
Method for treating amyloid disease
|
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
|
NZ567324A
(en)
*
|
2003-02-01 |
2009-08-28 |
Wyeth Corp |
Active immunization to generate antibodies to soluble A-beta
|
|
ES2344645T3
(es)
|
2003-02-10 |
2010-09-02 |
Applied Molecular Evolution, Inc. |
Moleculas de union al abeta.
|
|
US8663650B2
(en)
|
2003-02-21 |
2014-03-04 |
Ac Immune Sa |
Methods and compositions comprising supramolecular constructs
|
|
US7732162B2
(en)
|
2003-05-05 |
2010-06-08 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
|
|
TWI306458B
(en)
*
|
2003-05-30 |
2009-02-21 |
Elan Pharma Int Ltd |
Humanized antibodies that recognize beta amyloid peptide
|
|
CA2530172A1
(en)
|
2003-06-27 |
2005-02-10 |
Abgenix, Inc. |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
|
KR101139103B1
(ko)
*
|
2003-09-12 |
2012-07-05 |
아피리스 아게 |
아페레시스 장치
|
|
AT413336B
(de)
*
|
2003-09-12 |
2006-02-15 |
Mattner Frank Dr |
Apherese-vorrichtung
|
|
US7848543B2
(en)
*
|
2004-02-05 |
2010-12-07 |
Brainlab Ag |
Method and system for prediction and management of material and information transport in an organism
|
|
AU2005217596B2
(en)
*
|
2004-02-23 |
2012-01-19 |
Eli Lilly And Company |
Anti-ABeta antibody
|
|
JPWO2005105998A1
(ja)
*
|
2004-04-27 |
2008-07-31 |
財団法人化学及血清療法研究所 |
ヒト抗アミロイドβペプチド抗体およびその抗体フラグメント
|
|
CA2572602A1
(en)
*
|
2004-07-02 |
2006-02-09 |
Northwestern University |
Monolocal antibodies that target pathological assemblies of amyloid .beta. (abeta)
|
|
US20060024667A1
(en)
|
2004-07-29 |
2006-02-02 |
Karen Manucharyan |
Compositions and methods for Alzheimer's disease
|
|
BRPI0516572A
(pt)
*
|
2004-10-05 |
2008-09-16 |
Wyeth Corp |
métodos e composições para melhorar a produção de proteìnas recombinantes
|
|
US9907485B2
(en)
*
|
2004-10-15 |
2018-03-06 |
Brainlab Ag |
Targeted immunization and plaque destruction against Alzheimer's disease
|
|
US9924888B2
(en)
*
|
2004-10-15 |
2018-03-27 |
Brainlab Ag |
Targeted infusion of agents against parkinson's disease
|
|
US9901413B2
(en)
*
|
2004-10-15 |
2018-02-27 |
Brainlab Ag |
Targeted infusion of agents for treatment of ALS
|
|
JP2008523815A
(ja)
*
|
2004-12-15 |
2008-07-10 |
エラン ファーマ インターナショナル リミテッド |
認知の改善における使用のためのヒト化アミロイドβ抗体
|
|
US7625560B2
(en)
|
2004-12-15 |
2009-12-01 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
EP1838349A1
(en)
*
|
2004-12-15 |
2007-10-03 |
Neuralab, Ltd. |
Amyloid beta antibodies for use in improving cognition
|
|
EP1827493A4
(en)
*
|
2004-12-22 |
2009-09-30 |
Univ St Louis |
USE OF ANTI-ABETA ANTIBODIES FOR THE TREATMENT OF BRAIN TRAUMA
|
|
CA2589860A1
(en)
*
|
2005-01-24 |
2006-08-03 |
Amgen Inc. |
Humanized anti-amyloid antibody
|
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
|
ES2402650T3
(es)
|
2005-06-17 |
2013-05-07 |
Janssen Alzheimer Immunotherapy |
Métodos de purificación de anticuerpos anti A beta
|
|
KR20180058863A
(ko)
|
2005-11-30 |
2018-06-01 |
애브비 인코포레이티드 |
아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
|
|
PT1954718E
(pt)
|
2005-11-30 |
2014-12-16 |
Abbvie Inc |
Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
|
|
CA2632822C
(en)
|
2005-12-12 |
2018-08-28 |
Ruth Greferath |
A beta 1-42 specific monoclonal antibodies with therapeutic properties
|
|
NZ568241A
(en)
|
2005-12-12 |
2011-08-26 |
Hoffmann La Roche |
Antibodies against amyloid beta 4 with glycosylation in the variable region
|
|
WO2007113172A2
(en)
*
|
2006-03-30 |
2007-10-11 |
Glaxo Group Limited |
Antibodies against amyloid-beta peptide
|
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
|
CN101058608B
(zh)
*
|
2006-04-21 |
2011-02-23 |
杜如昱 |
人类抗Aβ1-32淀粉样蛋白抗体、其纯化方法及用途
|
|
EP3988566A1
(en)
*
|
2006-07-14 |
2022-04-27 |
AC Immune SA |
Humanized antibody against amyloid beta
|
|
NO348280B1
(no)
*
|
2006-07-14 |
2024-11-04 |
Genentech Inc |
Humanisert antistoff
|
|
SI2468770T1
(en)
*
|
2006-07-14 |
2018-05-31 |
Ac Immune S.A. |
A humanized antibody against amyloid beta.
|
|
PL2468770T3
(pl)
|
2006-07-14 |
2018-07-31 |
Ac Immune S.A. |
Humanizowane przeciwciało przeciw amyloidowi beta
|
|
PL2074145T3
(pl)
*
|
2006-10-02 |
2017-11-30 |
Ac Immune S.A. |
Humanizowane przeciwciało przeciw amyloidowi beta
|
|
BRPI0719250A2
(pt)
|
2006-10-12 |
2015-06-16 |
Wyeth Corp |
Métodos e composições com opalescência reduzida.
|
|
US8455626B2
(en)
*
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
|
DK2104682T3
(en)
|
2007-01-11 |
2017-01-16 |
Michael Bacher |
DIAGNOSIS AND TREATMENT OF ALZHEIMER'S AND OTHER DEMENTIA DISEASES
|
|
HRP20150237T1
(hr)
|
2007-01-18 |
2015-04-10 |
Eli Lilly And Company |
Pegilirani fab protiv amiloida-beta
|
|
AU2008215948A1
(en)
|
2007-02-12 |
2008-08-21 |
Merck & Co., Inc. |
Piperazine derivatives for treatment of AD and related conditions
|
|
US20100311767A1
(en)
|
2007-02-27 |
2010-12-09 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
|
CA2679446C
(en)
|
2007-03-01 |
2016-05-17 |
Probiodrug Ag |
New use of glutaminyl cyclase inhibitors
|
|
EP2146746A4
(en)
*
|
2007-04-18 |
2011-03-23 |
Janssen Alzheimer Immunotherap |
PREVENTIVE AND TREATING ZEREBRALER AMYLOID ANGIOPATHY
|
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
|
US9656991B2
(en)
|
2007-04-18 |
2017-05-23 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
|
CA2687330A1
(en)
|
2007-05-18 |
2008-11-27 |
The Johns Hopkins University |
A treatment simulator for brain diseases and method of use thereof
|
|
US20090232801A1
(en)
*
|
2007-05-30 |
2009-09-17 |
Abbot Laboratories |
Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
|
|
JP2010528583A
(ja)
*
|
2007-06-11 |
2010-08-26 |
エーシー イミューン ソシエテ アノニム |
アミロイドβに対するヒト化抗体
|
|
NZ599497A
(en)
*
|
2007-06-12 |
2013-11-29 |
Ac Immune Sa |
Humanized antibodies to amyloid beta
|
|
US8613923B2
(en)
|
2007-06-12 |
2013-12-24 |
Ac Immune S.A. |
Monoclonal antibody
|
|
ES2498040T3
(es)
|
2007-07-27 |
2014-09-24 |
Janssen Alzheimer Immunotherapy |
Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
|
|
CN101842388B
(zh)
*
|
2007-09-13 |
2013-09-04 |
德勒尼克斯治疗股份公司 |
针对β淀粉样肽的人源化抗体
|
|
BRPI0818621A8
(pt)
*
|
2007-10-05 |
2018-01-30 |
Ac Immune Sa |
composição farmacêutica, e, métodos para reduzir a carga da placa e a quantidade de placas na camada de célula de gânglio retinal de um indivíduo, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular, para diagnosticar uma doença ocular e uma predisposição a uma doença ocular, para monitorar doença ocular, para predizer responsividade de um paciente, e para reter ou diminuir pressão ocular nos olhos de um indivíduo
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
US8470321B2
(en)
|
2007-11-16 |
2013-06-25 |
The Rockefeller University |
Antibodies specific for the protofibril form of beta-amyloid protein
|
|
EP2261254A3
(en)
|
2007-12-21 |
2011-04-13 |
Amgen, Inc |
Anti-amyloid antibodies and uses thereof
|
|
EP2106802A1
(en)
|
2008-04-02 |
2009-10-07 |
SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. |
Modified peptides as synthetic vaccines in amyloid-associated disease
|
|
EP2149380A1
(en)
*
|
2008-07-29 |
2010-02-03 |
Medivet Pharma, S.L. |
Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
|
|
WO2010024927A2
(en)
|
2008-08-28 |
2010-03-04 |
The Research Foundation Of State University Of New York |
Treatment of amyloidoses using myelin basic protein and fragments thereof
|
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
|
US8614297B2
(en)
|
2008-12-22 |
2013-12-24 |
Hoffmann-La Roche Inc. |
Anti-idiotype antibody against an antibody against the amyloid β peptide
|
|
BR112012008346B1
(pt)
|
2009-09-11 |
2021-12-21 |
Vivoryon Therapeutics N.V. |
Derivados heterocíclicos, seu processo de preparação, e composição farmacêutica
|
|
DK2510359T3
(en)
|
2009-12-11 |
2015-12-07 |
Araclón Biotech S L |
METHODS AND REAGENTS FOR IMPROVED DETECTION OF AMYLOID-BETA PEPTIDES
|
|
US9102717B2
(en)
|
2010-03-01 |
2015-08-11 |
The J. David Gladstone Institutes |
Antibody specific for apolipoprotein and methods of use thereof
|
|
WO2011107530A2
(en)
|
2010-03-03 |
2011-09-09 |
Probiodrug Ag |
Novel inhibitors
|
|
DK2545047T3
(da)
|
2010-03-10 |
2014-07-28 |
Probiodrug Ag |
Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
|
|
MX336196B
(es)
|
2010-04-15 |
2016-01-11 |
Abbvie Inc |
Proteinas de union a amiloide beta.
|
|
EP2560953B1
(en)
|
2010-04-21 |
2016-01-06 |
Probiodrug AG |
Inhibitors of glutaminyl cyclase
|
|
WO2011149461A1
(en)
|
2010-05-27 |
2011-12-01 |
Medtronic, Inc. |
Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
|
|
US8822663B2
(en)
|
2010-08-06 |
2014-09-02 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP3533803B1
(en)
|
2010-08-14 |
2021-10-27 |
AbbVie Inc. |
Anti-amyloid-beta antibodies
|
|
DK4108671T3
(da)
|
2010-10-01 |
2025-01-06 |
Modernatx Inc |
Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
|
|
WO2012123563A1
(en)
|
2011-03-16 |
2012-09-20 |
Probiodrug Ag |
Benz imidazole derivatives as inhibitors of glutaminyl cyclase
|
|
JP5767393B2
(ja)
|
2011-03-31 |
2015-08-19 |
ファイザー・インク |
新規二環式ピリジノン
|
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
|
EP2511296A1
(en)
|
2011-04-12 |
2012-10-17 |
Araclón Biotech, S. L. |
Antibody, kit and method for determination of amyloid peptides
|
|
WO2012172449A1
(en)
|
2011-06-13 |
2012-12-20 |
Pfizer Inc. |
Lactams as beta secretase inhibitors
|
|
WO2013030713A1
(en)
|
2011-08-31 |
2013-03-07 |
Pfizer Inc. |
Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
JP2012050437A
(ja)
*
|
2011-09-12 |
2012-03-15 |
Janssen Alzheimer Immunotherapy |
ベータアミロイドペプチドを認識するヒト化抗体
|
|
JP6113737B2
(ja)
|
2011-10-03 |
2017-04-12 |
モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． |
修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
|
|
KR20140102759A
(ko)
|
2011-12-16 |
2014-08-22 |
모더나 세라퓨틱스, 인코포레이티드 |
변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
|
|
CN104114701A
(zh)
|
2011-12-22 |
2014-10-22 |
弗·哈夫曼-拉罗切有限公司 |
表达载体组织、新的生产用细胞产生方法及其在重组产生多肽中的用途
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
EP2834259A4
(en)
|
2012-04-02 |
2016-08-24 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES
|
|
JP6110937B2
(ja)
|
2012-05-04 |
2017-04-05 |
ファイザー・インク |
ＡＰＰ、ＢＡＣＥ１、およびＢＡＣＥ２の阻害剤としての複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
|
|
CN105732639A
(zh)
|
2012-06-29 |
2016-07-06 |
辉瑞大药厂 |
作为LRRK2抑制剂的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类
|
|
MX2014015744A
(es)
*
|
2012-07-03 |
2015-06-05 |
Janssen Sciences Ireland Uc |
Anticuerpos a-beta de epítopo de terminal c y central.
|
|
CA2882389A1
(en)
|
2012-09-20 |
2014-03-27 |
Pfizer Inc. |
Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
|
|
UA110688C2
(uk)
|
2012-09-21 |
2016-01-25 |
Пфайзер Інк. |
Біциклічні піридинони
|
|
US9597380B2
(en)
|
2012-11-26 |
2017-03-21 |
Modernatx, Inc. |
Terminally modified RNA
|
|
JP2016502978A
(ja)
|
2012-12-11 |
2016-02-01 |
ファイザー・インク |
ＢＡＣＥ１の阻害剤としてのヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
|
|
CA2893333C
(en)
|
2012-12-19 |
2017-10-24 |
Pfizer Inc. |
Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
|
|
CA2897678A1
(en)
|
2013-02-13 |
2014-08-21 |
Pfizer Inc. |
Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
|
|
US9233981B1
(en)
|
2013-02-15 |
2016-01-12 |
Pfizer Inc. |
Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
|
|
CA2900302C
(en)
|
2013-02-19 |
2018-07-03 |
Pfizer Inc. |
Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
SG11201509566RA
(en)
|
2013-05-20 |
2015-12-30 |
Genentech Inc |
Anti-transferrin receptor antibodies and methods of use
|
|
SG10201802525QA
(en)
|
2013-09-13 |
2018-04-27 |
Genentech Inc |
Methods and compositions comprising purified recombinant polypeptides
|
|
KR102332302B1
(ko)
|
2013-09-13 |
2021-12-01 |
제넨테크, 인크. |
세포주에서 숙주 세포 단백질 및 재조합 폴리펩티드 생성물을 검출 및 정량화하기 위한 조성물 및 방법
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
EP3052521A1
(en)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
JP6425717B2
(ja)
|
2013-10-04 |
2018-11-21 |
ファイザー・インク |
ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン
|
|
EP3083618B1
(en)
|
2013-12-17 |
2018-02-21 |
Pfizer Inc |
Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
|
|
EP3126361B1
(en)
|
2014-04-01 |
2019-11-06 |
Pfizer Inc |
Chromene and 1,1a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
|
|
AU2015245260A1
(en)
|
2014-04-10 |
2016-10-06 |
Pfizer Inc. |
2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides
|
|
WO2015165961A1
(en)
|
2014-04-29 |
2015-11-05 |
Affiris Ag |
Treatment and prevention of alzheimer's disease (ad)
|
|
WO2016012896A1
(en)
|
2014-07-24 |
2016-01-28 |
Pfizer Inc. |
Pyrazolopyrimidine compounds
|
|
CR20170035A
(es)
|
2014-08-06 |
2017-04-28 |
Pfizer |
Compuestos de imidazopiridazina
|
|
WO2016081643A1
(en)
|
2014-11-19 |
2016-05-26 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
|
ES2848376T3
(es)
|
2014-11-19 |
2021-08-09 |
Axon Neuroscience Se |
Anticuerpos de tau humanizados en la enfermedad de Alzheimer
|
|
JP6993228B2
(ja)
|
2014-11-19 |
2022-03-03 |
ジェネンテック， インコーポレイテッド |
抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
|
|
JP6628805B2
(ja)
|
2015-02-03 |
2020-01-15 |
ファイザー・インク |
新規シクロプロパベンゾフラニルピリドピラジンジオン
|
|
BR112017026191B1
(pt)
|
2015-06-17 |
2023-10-10 |
Pfizer Inc |
Compostos tricíclicos inibidores de fosfodiesterase, sua composição farmacêutica e uso dos mesmos
|
|
AU2016295650A1
(en)
|
2015-07-21 |
2018-01-25 |
Bioarctic Neuroscience Ab |
Method for treatment of traumatic brain injury targeting aggregated peptides
|
|
WO2017032686A1
(en)
|
2015-08-21 |
2017-03-02 |
F. Hoffmann-La Roche Ag |
Method for the reduction of host cell proteins in affinity chromatography
|
|
CN108137586B
(zh)
|
2015-09-14 |
2021-04-13 |
辉瑞大药厂 |
作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
|
|
WO2017051294A1
(en)
|
2015-09-24 |
2017-03-30 |
Pfizer Inc. |
N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors
|
|
AU2016325665A1
(en)
|
2015-09-24 |
2018-03-08 |
Pfizer Inc. |
N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
|
|
JP2018531924A
(ja)
|
2015-09-24 |
2018-11-01 |
ファイザー・インク |
テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
CA3003435A1
(en)
|
2015-10-28 |
2017-05-04 |
The Trustees Of The University Of Pennsylvania |
Intrathecal administration of adeno-associated-viral vectors for gene therapy
|
|
HK1259325A1
(zh)
|
2015-11-09 |
2019-11-29 |
英属哥伦比亚大学 |
淀粉样蛋白β中的N-末端表位及其构象选择性抗体
|
|
CN108350052A
(zh)
*
|
2015-11-09 |
2018-07-31 |
英属哥伦比亚大学 |
淀粉样蛋白β中间区域中的表位及其构象选择性抗体
|
|
KR20180094876A
(ko)
|
2015-11-09 |
2018-08-24 |
더 유니버시티 오브 브리티쉬 콜롬비아 |
아밀로이드 베타 에피토프 및 이에 대한 항체
|
|
US10323042B2
(en)
|
2016-02-23 |
2019-06-18 |
Pfizer Inc. |
6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
|
|
TWI735600B
(zh)
|
2016-07-01 |
2021-08-11 |
美商美國禮來大藥廠 |
抗－N3pGlu類澱粉β肽抗體及其用途
|
|
MX386258B
(es)
|
2016-07-01 |
2025-03-18 |
Pfizer |
Derivados de 5,7-dihidro-pirrolo-piridina para tratar enfermedades neurologicas y neurodegenerativas
|
|
US12071472B2
(en)
|
2016-07-18 |
2024-08-27 |
The University Of British Columbia |
Methods of reducing toxicity induced by Amyloid beta (A-beta) oligomers using antibodies specific to A-beta oligomers
|
|
CA3032692A1
(en)
|
2016-08-09 |
2018-02-15 |
Eli Lilly And Company |
Combination antibody therapy for the treatment of neurodegenerative diseases
|
|
CA3035080A1
(en)
|
2016-09-27 |
2018-04-05 |
Cero Therapeutics, Inc. |
Chimeric engulfment receptor molecules
|
|
EP3532034A4
(en)
|
2016-10-28 |
2020-12-02 |
Washington University |
ANTI-APOE ANTIBODY
|
|
US20180125920A1
(en)
|
2016-11-09 |
2018-05-10 |
The University Of British Columbia |
Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
|
|
IL269215B
(en)
|
2017-03-10 |
2022-09-01 |
Pfizer |
Disubstituted imidazole[4,5-c]quinoline derivatives
|
|
KR102582626B1
(ko)
|
2017-03-10 |
2023-09-22 |
화이자 인코포레이티드 |
Lrrk2 억제제로서의 신규 이미다조[4,5-c]퀴놀린 유도체
|
|
JOP20190247A1
(ar)
*
|
2017-04-20 |
2019-10-20 |
Lilly Co Eli |
أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
|
|
EP3634978A1
(en)
|
2017-06-07 |
2020-04-15 |
Adrx, Inc. |
Tau aggregation inhibitors
|
|
PL3642202T3
(pl)
|
2017-06-22 |
2023-03-13 |
Pfizer Inc. |
Pochodne dihydropirolopirydyny
|
|
US11530257B2
(en)
|
2017-06-29 |
2022-12-20 |
The Trustees Of Columbia University In The City Of New York |
Chimeric antibodies for treatment of amyloid deposition diseases
|
|
ES2984844T3
(es)
|
2017-07-18 |
2024-10-31 |
Univ British Columbia |
Anticuerpos contra beta amiloide
|
|
US12286469B2
(en)
|
2017-07-18 |
2025-04-29 |
The University Of British Columbia |
Humanized antibodies binding to amyloid-beta (A-beta)
|
|
JP7368856B2
(ja)
|
2017-07-25 |
2023-10-25 |
トゥルーバインディング，インコーポレイテッド |
Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
|
|
US11382974B2
(en)
|
2017-08-01 |
2022-07-12 |
The Trustees Of Columbia University In The City Of New York |
Methods and compositions for treatment of amyloid deposition diseases
|
|
EP3668886A2
(en)
|
2017-08-18 |
2020-06-24 |
Adrx, Inc. |
Tau aggregation peptide inhibitors
|
|
JP7286658B2
(ja)
|
2017-09-26 |
2023-06-05 |
セロ・セラピューティクス・インコーポレイテッド |
キメラエンガルフメント受容体分子および使用方法
|
|
PL3461819T3
(pl)
|
2017-09-29 |
2020-11-30 |
Probiodrug Ag |
Inhibitory cyklazy glutaminylowej
|
|
US20200330592A1
(en)
*
|
2017-10-09 |
2020-10-22 |
Keith Black |
Compositions and methods of treating alzheimer's and other amyloid related diseases
|
|
CA3094366A1
(en)
|
2018-03-23 |
2019-09-26 |
Pfizer Inc. |
Piperazine azaspiro derivatives
|
|
AU2019243154A1
(en)
|
2018-03-28 |
2020-10-01 |
Cero Therapeutics, Inc. |
Cellular immunotherapy compositions and uses thereof
|
|
WO2019191332A1
(en)
|
2018-03-28 |
2019-10-03 |
Cero Therapeutics, Inc. |
Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
|
|
US20210309726A1
(en)
*
|
2018-05-21 |
2021-10-07 |
New York University |
Treatment of melanoma brain metastasis by inhibition of amyloid precursor protein cleavage
|
|
US12018069B2
(en)
|
2018-06-28 |
2024-06-25 |
The Trustees Of Columbia University In The City Of New York |
Methods and compositions for imaging amyloid deposits
|
|
WO2020072357A1
(en)
|
2018-10-04 |
2020-04-09 |
University Of Rochester |
Improvement of glymphatic delivery by manipulating plasma osmolarity
|
|
EP3898667A2
(en)
|
2018-12-20 |
2021-10-27 |
F. Hoffmann-La Roche AG |
Modified antibody fcs and methods of use
|
|
FR3091999A1
(fr)
*
|
2019-01-25 |
2020-07-31 |
Mexbrain |
Dispositif d’extraction conjointe d’un cation métallique et d’une molécule cible
|
|
CN120058944A
(zh)
|
2019-01-30 |
2025-05-30 |
真和制药有限公司 |
抗gal3抗体及其用途
|
|
CN114555792A
(zh)
|
2019-10-15 |
2022-05-27 |
伊莱利利公司 |
重组改造的、脂肪酶/酯酶缺陷型哺乳动物细胞系
|
|
JP2023528797A
(ja)
|
2020-05-26 |
2023-07-06 |
トゥルーバインディング，インコーポレイテッド |
ガレクチン－３を遮断することにより炎症性疾患を処置する方法
|
|
MX2023000949A
(es)
|
2020-07-23 |
2023-02-22 |
Othair Prothena Ltd |
Anticuerpos anti-beta-amiloide (abeta).
|
|
TWI843040B
(zh)
|
2021-01-11 |
2024-05-21 |
美商美國禮來大藥廠 |
抗N3pGlu類澱粉β抗體及其用途
|
|
WO2022182658A1
(en)
|
2021-02-23 |
2022-09-01 |
Hoth Therapeutics, Inc. |
Use of aprepitant for treating alzheimer's disease
|
|
TW202300517A
(zh)
|
2021-03-12 |
2023-01-01 |
美商美國禮來大藥廠 |
抗類澱粉β抗體及其用途
|
|
TW202300518A
(zh)
|
2021-03-12 |
2023-01-01 |
美商美國禮來大藥廠 |
抗N3pGlu類澱粉β抗體及其用途
|
|
WO2022251048A1
(en)
|
2021-05-24 |
2022-12-01 |
Eli Lilly And Company |
Anti-amyloid beta antibodies and uses thereof
|
|
IL314657A
(en)
|
2022-02-03 |
2024-09-01 |
Lilly Co Eli |
Regional tau imaging for diagnosing and treating alzheimer's disease
|
|
AU2024322991A1
(en)
|
2023-08-09 |
2026-01-08 |
F. Hoffmann-La Roche Ag |
Anti-a-beta protein antibodies, methods and uses thereof
|
|
WO2025145091A1
(en)
|
2023-12-29 |
2025-07-03 |
Pfizer Inc. |
Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases
|